ALLO – allogene therapeutics, inc. (US:NASDAQ)

DELAYED
$ usd
Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low
VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close
1D
5D
1M
3M
YTD
1Y
3Y
1 Day ALLO SPY QQQ SPX
Date
Time
Symbol
Company Name
Action
%Chg
3/12/2026
04:02 pm
allo
allogene therapeutics, inc.
BEAT
-3.6%
11/6/2025
04:05 pm
allo
allogene therapeutics, inc.
BEAT
12.4%
8/13/2025
04:05 pm
allo
allogene therapeutics, inc.
BEAT
0.9%
5/13/2025
04:05 pm
allo
allogene therapeutics, inc.
IN-LINE
-16.4%
Earnings are essential to understanding the financial health of a company listed on any Stock Exchange. But what are Earnings, how are they calculated, when are they announced, and how are they used to make sound investment decisions?
The answers are right here.
Stock Stats
News Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
Order Stats
Sub-Penny
Odd Lot
Avg. bid-ask spread
Avg. bid / ask size
Shares at ask / bid
Off exchange
Top News Gainers
2/6 Allogene Therapeutics Announces February and March 2020 Investor Conference Schedule 6.8%
3/18 Form 4 Allogene Therapeutics, For: Mar 16 Filed by: Chang David D 6.8%
3/17 Allogene Therapeutics Inc (NASDAQ: ALLO) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 6.7%
4/23 Form DEF 14A Allogene Therapeutics, For: Dec 31 5.9%
4/28 Form 4 Allogene Therapeutics, For: Apr 24 Filed by: Chang David D 5.9%
4/17 Allogene Therapeutics Inc (NASDAQ: ALLO) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 5.5%
8/7 Allogene Therapeutics, Inc. (ALLO) CEO David Chang on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] 5.0%
3/24 MaxCyte and Allogene Therapeutics Sign Clinical and Commercial License Agreement to Enable the Advancement of Allogeneic CAR T (AlloCAR T™) Therapies 4.9%
3/13 Allogene Therapeutics Inc (NASDAQ: ALLO) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $35.00 price target on the stock. 4.7%
2/24 Form 4 Allogene Therapeutics, For: Feb 20 Filed by: SCHMIDT ERIC THOMAS 4.4%
Top News Decliners
3/12 Allogene Therapeutics Inc (NASDAQ: ALLO) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -15.8%
11/6 Allogene Therapeutics Inc (NASDAQ: ALLO) had its "hold" rating re-affirmed by analysts at JPMorgan Chase & Co.. They now have a $29.00 price target on the stock. -6.4%
8/11 Allogene Therapeutics Inc (NASDAQ: ALLO) had its "hold" rating re-affirmed by analysts at JPMorgan Chase & Co.. They now have a $29.00 price target on the stock. -5.4%
8/12 Allogene Therapeutics Inc (NASDAQ: ALLO) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.2%
3/20 Senator Richard Burr Sold a Fortune in Stocks While Playing Down Coronavirus Threat [The New York Times] -5.1%
11/12 Allogene Moves Forward With CAR-T Therapy Pipeline [Seeking Alpha] -5.1%
4/1 Allogene Therapeutics Announces Participation in Two Upcoming Virtual Investor Conferences -4.9%
9/25 Form 4 Allogene Therapeutics, For: Sep 23 Filed by: Kazam Joshua A -4.8%
5/22 Allogene Therapeutics Inc (NASDAQ: ALLO) is now covered by analysts at Stifel Nicolaus. They set a "hold" rating on the stock. -4.8%
11/5 Q3/2019 9/30/2019 EPS -0.500 ZacksConsensus -0.540 ActVsEst 0.040 - Beat -4.4%

Don’t Miss Out On The Next BIG Stock Move

Thanks for submitting the form.
ALLO – allogene therapeutics, inc. (US:NASDAQ)
DELAYED
$ usd
1D
5D
1M
3M
YTD
1Y
3Y
Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low
VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close
ALLO
SPY
QQQ
SPX
ALLO – allogene therapeutics, inc. (US:NASDAQ)
DELAYED
$ usd
1D
5D
1M
3M
YTD
1Y
3Y
Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low
VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close
ALLO SPY QQQ SPX
Stock Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
Sub-Penny
Odd Lot
Avg. bid-ask spread
Avg. bid / ask size
Shares at ask / bid
Off exchange
Stock Stats
Order Stats
Sub-Penny
Odd Lot
Avg. bid-ask spread
Avg. bid / ask size
Shares at ask / bid
Off exchange
News Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
News
3/13
02:48 pm
allo
Neutral
Allogene Therapeutics (ALLO) had its "buy" rating reaffirmed by Canaccord Genuity Group Inc.. They now have a $14.00 price target on the stock.
3/13
12:38 pm
allo
Low
Allogene Therapeutics (ALLO) had its price target raised by Piper Sandler from $7.00 to $8.00. They now have an "overweight" rating on the stock.
3/12
11:19 pm
allo
Medium
Allogene Therapeutics Inc (ALLO) Q4 2025 Earnings Call Highlights: Financial Stability and ... [Yahoo! Finance]
3/12
10:04 pm
allo
Medium
Allogene Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
3/12
04:10 pm
allo
Medium
Allogene Therapeutics GAAP EPS of -$0.17 beats by $0.05 [Seeking Alpha]
3/12
04:02 pm
allo
Medium
Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update 
3/3
10:52 pm
allo
Neutral
Allogene Therapeutics Teases April ALPHA3 Futility Data, Details Autoimmune CAR-T Program at TD Cowen [Yahoo! Finance]
3/2
08:54 am
allo
Low
Allogene Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update [Yahoo! Finance]
3/2
08:30 am
allo
Low
Allogene Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update
3/12/2026
04:02 pm
allo
-3.6%
BEAT
11/6/2025
04:05 pm
allo
12.4%
BEAT
8/13/2025
04:05 pm
allo
0.9%
BEAT
5/13/2025
04:05 pm
allo
-16.4%
IN-LINE
Earnings are essential to understanding the financial health of a company listed on any Stock Exchange. But what are Earnings, how are they calculated, when are they announced, and how are they used to make sound investment decisions? The answers are right here.
3/13
02:06 pm
Maintains
Buy
Buy
Canaccord Genuity
Low
0.0%
1/9
07:00 am
Upgrades
Market Perform
Outperform
Citigroup Inc.
Medium
5.6%
1/9
06:10 am
Upgrades
Strong-Buy
UBS Group AG
Medium
3.6%
1/7
03:15 pm
Initiates
Buy
UBS
Low
-1.3%
1/7
09:07 am
Initiates
Buy
UBS Group AG
Medium
3.5%
1/7
08:18 am
Initiates
BUY
UBS
Medium
4.2%
3/18
04:07 pm
allo
Medium
Form 4 Allogene Therapeutics, For: Mar 16 Filed by: Beneski Benjamin Machinas
3/18
04:07 pm
allo
Medium
Form 4 Allogene Therapeutics, For: Mar 16 Filed by: Chang David D
3/16
08:20 pm
allo
Medium
Form 144 Allogene Therapeutics, Filed by: Beneski Benjamin Machinas
3/16
08:05 pm
allo
Medium
Form 144 Allogene Therapeutics, Filed by: Chang David D
3/12
04:37 pm
allo
Medium
Form S-8 Allogene Therapeutics,
3/12
04:12 pm
allo
Medium
Form 10-K Allogene Therapeutics, For: Dec 31
3/12
04:07 pm
allo
Medium
Form 8-K Allogene Therapeutics, For: Mar 12
3/4
05:42 pm
allo
Medium
Form 4 Allogene Therapeutics, For: Mar 02 Filed by: Beneski Benjamin Machinas
3/2
09:05 pm
allo
Medium
Form 144 Allogene Therapeutics, Filed by: Beneski Benjamin Machinas
Show more
Top News Gainers
2/6 Allogene Therapeutics Announces February and March 2020 Investor Conference Schedule 6.8%
3/18 Form 4 Allogene Therapeutics, For: Mar 16 Filed by: Chang David D 6.8%
3/17 Allogene Therapeutics Inc (NASDAQ: ALLO) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 6.7%
4/23 Form DEF 14A Allogene Therapeutics, For: Dec 31 5.9%
4/28 Form 4 Allogene Therapeutics, For: Apr 24 Filed by: Chang David D 5.9%
4/17 Allogene Therapeutics Inc (NASDAQ: ALLO) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 5.5%
8/7 Allogene Therapeutics, Inc. (ALLO) CEO David Chang on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] 5.0%
3/24 MaxCyte and Allogene Therapeutics Sign Clinical and Commercial License Agreement to Enable the Advancement of Allogeneic CAR T (AlloCAR T™) Therapies 4.9%
3/13 Allogene Therapeutics Inc (NASDAQ: ALLO) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $35.00 price target on the stock. 4.7%
2/24 Form 4 Allogene Therapeutics, For: Feb 20 Filed by: SCHMIDT ERIC THOMAS 4.4%
Top News Decliners
3/12 Allogene Therapeutics Inc (NASDAQ: ALLO) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -15.8%
11/6 Allogene Therapeutics Inc (NASDAQ: ALLO) had its "hold" rating re-affirmed by analysts at JPMorgan Chase & Co.. They now have a $29.00 price target on the stock. -6.4%
8/11 Allogene Therapeutics Inc (NASDAQ: ALLO) had its "hold" rating re-affirmed by analysts at JPMorgan Chase & Co.. They now have a $29.00 price target on the stock. -5.4%
8/12 Allogene Therapeutics Inc (NASDAQ: ALLO) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.2%
3/20 Senator Richard Burr Sold a Fortune in Stocks While Playing Down Coronavirus Threat [The New York Times] -5.1%
11/12 Allogene Moves Forward With CAR-T Therapy Pipeline [Seeking Alpha] -5.1%
4/1 Allogene Therapeutics Announces Participation in Two Upcoming Virtual Investor Conferences -4.9%
9/25 Form 4 Allogene Therapeutics, For: Sep 23 Filed by: Kazam Joshua A -4.8%
5/22 Allogene Therapeutics Inc (NASDAQ: ALLO) is now covered by analysts at Stifel Nicolaus. They set a "hold" rating on the stock. -4.8%
11/5 Q3/2019 9/30/2019 EPS -0.500 ZacksConsensus -0.540 ActVsEst 0.040 - Beat -4.4%